Alzheimer's disease epidemiology, genetics and pathogenic hypotheses;MALADIE D'ALZHEIMER, EPIDEMIOLOGIE, GENETIQUE ET HYPOTHESES PHYSIOPATHOLOGIQUES

Presse Medicale

Volumn 27, Issue 15, 1998, Pages 725-730

  Blain, H ^a   Jeandel, C ^a  

^a CHU NANCY BRABOIS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM; AMYLOID; AMYLOID BETA PROTEIN; DRINKING WATER; ESTROGEN; NONSTEROID ANTIINFLAMMATORY AGENT;

AGED; AGING; ALZHEIMER DISEASE; CIGARETTE SMOKING; DEVELOPMENTAL GENETICS; FAMILY; GENETICS; HEAD INJURY; HUMAN; MICROGLIA; NERVE DEGENERATION; OXIDATIVE STRESS; REVIEW; RISK FACTOR; SENILE PLAQUE; AGE; FEMALE; FRANCE; MALE; MIDDLE AGED; PATHOPHYSIOLOGY;

AGE FACTORS; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; FEMALE; FRANCE; HUMANS; MALE; MIDDLE AGED; RISK FACTORS;

EID: 0032542842     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (100)

1. Kawas CH. Epidemiology of Alzheimer disease. Neurology 1995 ; 143:13-21.
2. Rocca WA, Hofman A, Brayne C et al. Frequency and distribution of alzheimer's disease in Europe: a collaborative study of 1980-1990 findings. Ann Neurol 1991 ; 381:381-90.
3. Ritchie K, Kildea D. Is senile dementia "age-related" or "ageing-related"? -evidence from meta-analysis of dementia prevalence in the oldest old. Lancet 1995 ; 346:931-3.
4. Bachman DL, Wolf PA, Linn RT et al. Incidence of dementia and probable Alzheimer's disease in a general population : the Framingham study. Neurology 1993 ; 43:515-9.
5. Hebert LE, Scherr PA, Beckett LA et al. Age-specific incidence of Alzheimer's disease in a community population. JAMA 1995 ; 273:1354-9.
6. Aevarsson O, Skoog I. A population-based study on the incidence of dementia disorders between 85 and 88 years of age. J Am Geriatr Soc 1996 ; 44:1455-60.
7. Letenneur L, Commenges D, Dartigues JF, Barberger-Gateau P. Incidence of dementia and Alzheimer's disease in elderly community residents of south-western France. Int J Epidemiol 1994 ; 23:1256-61.
8. Roman GC, Tatemichi TK, Erkinjuntti T et al. Vascular dementia : diagnostic criteria for research studies. Report of the NINDS-AIREN international Work Group. Neurology 1993 ; 43:250-60.
9. The Lund and Manchester Croups. Clinical and neuropathological criteria for fronto-temporal dementia. J Neurol Neurosurg Psychiatry 1994 ; 57:416-8.
10. Mc Keith IG, Galasko D, Kosaka K et al. Clinical and pathological diagnosis of dementia with Lewy bodies (DLB). Report of the CDLB international workshop. Neurology 1996 ; 47:1113-24.
11. e âge. Bull Acad Natle Méd 1996 ; 7:1715-29.
12. Hofman A, Rocca WA, Brayne C et al. The prevalence of dementia in Europe : a collaborative study of 1980-1990 findings. Int J Epidemiol 1991 ; 20:381-90.
13. Radebaugh TS, Buckholtz NS, Khachaturian ZS. Fischer symposium : strategies for the prevention of Alzheimer disease; overview of research planning meeting III. Alzheimer Dis Assoc Disord 1996 ; 10:1-5.
14. Fratiglioni L, Viitanen M, Von Strauss E, Tontodonati V, Herlitz A, Winblad B. Very old women at highest risk of dementia and Alkzheimer's disease : incidence data from the Kungsholmen Project, Stockholm. Neurology 1997 ; 48:132-8.
15. Doll R. Review : Alzheimer's disease and environmental survival bias. Age Ageing 1993 ; 22:138-53.
16. Mc Lachlan DR, Bergeron C, Smith JE, Boomer D, Rifat SL. Risk for neuropathologically confirmed Alzheimer's disease and residual aluminium in municipal drinking water employing weighted residential histories. Neurology 1996 ; 46:401-5.
17. Ott A, Stolk RP, Hofman A, Van Harskamp F, Grobbee DE, Breteler MM. Association of diabetes mellitus and dementia : the Rotterdam Study. Diabetologia 1996 ; 39:1392-7.
18. Sobel E, Davanipour Z, Sulkava R et al. Occupations with exposure to electromagnetic fields: a possible risk factor for Alzheimer's disease. Am J Epidemiol 1995 ; 142:515-24.
19. Schofield PW, Tang M, Marder K et al. Alzheimer's disease after remote head injury : an incidence study. J Neurol Neurosurg Psychiatry 1997 ; 62:119-24.
20. Katzman R. Education and the prevalence of dementia and Alzheimer's disease. Neurology 1993 ; 43:13-20.
21. Lee PN. Smoking and Alzheimer's disease : a review of the epidemiological evidence. Neuroepidemiology 1994 ; 43:13-20.
22. Letenneur L, Dartigues JF, Commenges D, Barberger-Gateau P, Tessier JF, Orgogozo JM. Tobacco consumption and cognitive impairment in elderly people. A population-based study. Ann Epidemiol 1994 ; 4:449-54.
23. Riggs JE. The protective influence of cigarette smoking on Alzheimer's and Parkinson's diseases. Quamire or opportinity for neuroepidemiology? Neural Clin 1996 ; 14:353-8.
24. Andersen K, Launer LJ, Ott A, Hoes AW, Breteler MM, Hofman A. Do non steroidal anti-inflammatory drugs decrease the risk for Alzheimer's disease? The Rotterdam Study. Neurology 1995 ; 45:1441-5.
25. Stewart WF, Kawas C, Corrada M, Metter EJ. Risk of Alzheimer's disease and duration of NSAID use. Neurology 1997 ; 48:626-32.
26. Fillit H. Future therapeutic developments of estrogen use. J Clin Pharmacol 1995 ; 35:S25-8.
27. Robinson D, Fireadman L, Marcus R et al. Estrogen replacement and memory in older women. JAGS 1994 ; 42:919-22.
28. Henderson VW, Paganini-Hill A, Emanuel C. Estrogen replacement therapy in older women. Comparison between Alzheimer's disease cases and nondemented subjects. Arch Neurol 1994 ; 51(9):896-900.
29. Paganini-Hill A, Henderson V. Estrogen deficiency and risk of Alzheimer's disease. Am J Epidemiol 1994 ; 140:256-61.
30. Schneider L, Farlow MR. Predicting response to cholinesterases inhibitors. Possible approaches. CNS drugs 1995 ; 4:114-24.
31. Jaffe AB, Toran-Allerand D, Greengard P. Estrogen regulates metabolism of Alzheimer Amyloid beta precursor protein. J Biol Chem 1994 ; 269:13065-8.
32. Stephenson J. More evidence links NSAID, estrogen use with reduced Alzheimer risk. JAMA 1996 ; 275:1389-90.
33. Paganini-hill A, Henderson VW. Estrogen replacement therapy and risk of Alzheimer disease. Arch Intern Med 1996 ; 156:2213-17.
34. Van Duijn CM. Epidemiology of the dementias: recent development and new approaches. J Neurol Neurosurg Psychiatr 1996 ; 60:478-88.
35. Alpers Vitch A, Berr C. Les facteurs de risque de la maladie d'Alzheimer. Approche épidémiologique. Bull Acad Natle Med 1996 ; 7:1673-85.
36. Edland SD, Silverman JM, Peskind ER, Tsuang D, Wijsman E, Morris JC. Increased risk of dementia in mothers of Alzheimer's disease cases : evidence for maternal inheritance. Neurology 1996 ; 47:254-6.
37. Duara R, Barker WW, Lopez-Alberola R et al. Alzheimer's disease: interaction of apolipoprotein E genotype, family history of dementia, gender, education, ethnicity, and age of onset. Neurology 1996 ; 46:1575-9.
38. Bergem AL, Engedal K, Kringlen E. The role of hereditary in late onset Alzheimer disease and vascular dementia. A twin study. Arch Gen Psychiatry 1997 ; 54:264-70.
39. Gatz M, Pedersen NL, Berg S et al. Heritability for Alzheimer's disease: the study of dementia in Swedish twins. J Gerontol A Biol Sci Med Sci 1997 ; 52:117-25.
40. Sherrington R, Rogaev EI, Liang Y et al. Cloning a novel gene bearing missense mutations in early Familial Alzheimer Disease. Nature 1995 ; 375:754-60.
41. Campion D, Flaman JM, Brice A et al. Mutations of the presenilin 1 gene in families with early-onset Alzheimer's disease. Human Mol Genet 1995 ; 4:2373-7.
42. Hutton M, Fuldner R, Froelich S et al. The structure of the Presenilin 1 (S182) gene and identification of six novel mutations in early onset AD families. Nature Genet 1995 ; 11:219-22.
43. Levy-Lahad E, Wasco W, Poorkaj P et al. Candidate gene for the chromosome 1 familial Alzheimer's disease locus. Science 1995 ; 269:973-7.
44. Levy-Lahad E, Wijman E, Nemens E et al. A familial Alzheimer's disease locus on chromosome 1. Science 1995 ; 269:970-3.
45. Bugiani O, Giaccone G, Verga L et al. bPP participates in PrP-amyloid plaques of Gerstmann-Straussler-Scheinker disease, Indiana Kindred. J Neuropathol Exp Neurol 1993 ; 52:64-70.
46. Amouyel P, Brousseau T, Fruchart JC, Dallongeville J. Apolipoprotein Σ e4 allele and Alzheimer's disease. Lancet 1993 ; 342:1309.
47. Strittmatter WJ, Saunders AM, Schmechel D, Perikak-Vance MA, Roses AD. Apolipolipoprotein E: high avidity binding to ß amyloid and increased frequency of type 4 allele in late-onset famillial Alzheimer's disease. Proc Natl Acad Sci USA 1993 ; 90:1977-81.
48. Wragg M, Hutton M, Talbot C. Genetic association between intronic polymorphism in presenilin gene and late-onset Alzheimer's disease. Lancet 1996 ; 347:509-12.
49. Kehoe P, William J, Holmans P et al. Association between a PS-1 intronic polymorphism and late onset Alzheimer's disease. Neuroreport 1996 ; 7:2155-8.
50. Brousseau T, Legrain S, Berr C, Gourlet V, Vidal O, Amouyel P. Confirmation of the epsilon 4 allele of the apolipoprotein E gene as a risk factor for late-onset Alzheimer's disease. Neurology 1994 ; 44:342-4.
51. Lucotte G, Davis F, Visvikis S et al. Apolipoprotein E-4 allele and Alzheimer's disease. Lancet 1993 ; 342:1309.
52. bis. Lucotte G, Visvikis D, Leininger-Muller B et al. Association of apolipoprotein E allele epsilon 4 with late-onset sporadic Alzheimer's disease. Am J Med 1994 ; 54:286-8.
53. Khachaturian K. Can new findings about the genetics of Alzheimer's disease ward off this callous thief of mind and spirit? The Sciences 1997 ; 37:20-5.
54. Duyckerts C, Hauw JJ, Bastenaire F et al. Laminar distribution of neocortical plaques in senile dementia of the Alzheimer type. Acta Neuropath 1986 ; 70:249-56.
55. Schmidt ML. Monoclonal antibodies to a 100-kd protein reveal abundant A beta-negative plaques throughout gray matter of Alzheimer's disease brain. Am J Pathol 1997 ; 151:68-70.
56. Duyckerts C, Bennecib M, Grignon Y, Piette F, Hauw JJ. La topographie des lésions de la maladie d'Alzheimer permet-elle de soupçonner leur mécanisme ? Bull Acad Natle Méd 1996 ; 180:1703-14.
57. Danenboerg HD, Haring R, Fisher A, Pittel Z, Gurwitz D, Heldman E. Dehydroepiandrosterone (DHEA) increases production and release of Alzheimer's amyloid precursor protein. Life Sci 1996 ; 59:1651-7.
58. Lee RKK, Arali W, Wurtman RJ. Stimulation of amyloid precursor protein synthesis syadrenergic receptors coupled to cAMP formation. Proc Natl Acad Sci 1997 ; 94:5422-6.
59. Kovacs D, Fausett H, Page K et al. Alzheimer-associated presenilins 1 and 2: neuronal expression in brain and localization to intracellular membranes in mammalian cells. Nature Med 1996 ; 2:224-9.
60. Uchihara T, El Hachimi H, Duyckaerts C et al. Widespread immunoreactivity of presenilin in neurons of normal and Alzheimer disease brain : study double labelling immunohistochemical. Acta Neuropathol 1996 ; 92:325-30.
61. Weber LL, Leissring MA, Yang AY, Glabe CG, Cribbs DH, La Ferla FM. Presenilin-1 immunoreactivity is localized intracellulary in Alzheimer's disease brain, but not detected in amyloid plaques. Exp Neurol 1997 ; 143:37-44.
62. Lemere CA, Lopera F, Kosik KS et al. The E280A presenilin 1 Alzheimer mutation produces increased A beta 42 deposition and severe cerebellar pathology. Nat Med 1996 ; 2:1146-50.
63. Citron M, Westaway D, Xia W et al. Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid beta-protein in both transfected cells and transgenic mice. Nat Med 1997 ; 3:67-72.
64. Lee MK, Borchelt DR, Kim G, Thinakaran G, Slunt HH, Ratovitski T, Martin LJ, Kittur A, Gandy S, Levey AI, Jenkins N, Copeland N, Price DL, Sisodia SS. Nat Med 1997 ; 3:756-60.
65. Beyreuther K, Masters C. Serpents on the road to dementia and death. Accumulative evidence from the mutant protein contributes to deposition of amyloid plaques in Alzheimer's disease. Nat Med 1997 ; 3:723-5.
66. Giannakopoulos P, Bouras C, Kovari E, Shioi J, Tezapsidis N, Hof PR, Robakis NK. Presenilin-1 immunoreactive neurons are preserved in late-onset Alzheimer's disease. Am J Pathol 1997 ; 150:429-36.
67. Delaère P, Duyckaerts C, Master C, Piette F, Hauw JJ. Large amounts of neocortical bA4 deposits in Alzheimer changes in a non demented case. Neurosci Let 1990 ; 116:87-93.
68. Berr C, Hauw JJ, Delaere P, Amouyel P. Apolipoprotein E allele epsilon 4 is linked to increased deposition of amyloid beta-peptide (A-beta) in cases with or without Alzheimer's disease. Neurosci Lett 1994 ; 178:221-4.
69. Munch G, Mayer S, Michaelis J et al. Influence of advanced glycation end-products and AGE-inhibitors on nucleation-dependent polymerization of beta-amyloid peptide. Biochem Biophys Acta 1997 ; 1360:17-29.
70. Finch CE, Cohen DM. Aging, metabolism and Alzheimer disease : review and hypotheses. Exp Neurol 1997 ; 143:82-102.
71. Sayer AA, Cooper C. Undernutrition and aging. Gerontology 1997 ; 43:203-5.
72. Blain H, Merched A, Visvikis S et al. Maladie d'Alzheimer et hypothèses impliquant les apolipoprotéines E. Presse Med 1996 ; 25:763-8.
73. Ma J, Brewer HB, Potter H. Alzheimer A beta neurotoxicity : promotion by antichymotrypsin, apoE4 ; inhibition by A-beta-related peptides. Neurobiol Aging 1996 ; 17:773-80.
74. Sopher BL, Fukuchi K, Kavanagh TJ, Furlong CE, Martin GM. Neurodegenerative mechanisms in Alzheimer's disease. A role for oxidative damage in amyloid beta protein precursor-mediated cell death. Mol Chem Neuropathol 1996 ; 29:153-68.
75. Bancher C, Jellinger KA. Neurofibrillary predominant form of Alzheimer's disease: a rare subtype in very old subjects. Acta Neuropathol 1994 ; 88:565-70.
76. bis Chang JW, Coleman PD, O'Banion MK. Prostaglandin G/H synthase-2 (cyclooxygenase-2) mRNA expression is decreased in Alzheimer's disease. Neurobiol Aging 1996 ; 17:801-8.
77. Mc Geer PL, Schulzer M, Mc Geer EG. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease : a review of 17 epidemiologic studies. Neurology 1996 ; 47:425-32.
78. Hull M, Fiebich BL, Lieb K, Strauss S, Berger SS, Volk B, Bauer J. Interleukin-6 associated inflammatory processes in Alzheimer's disease : new therapeutic options. Neurobiol Aging 1996 ; 17:795-800.
79. Pereira HA, Kumar P, Grammas P. Expression of CAP37, a novel inflammatory mediator, in Alzheimer's disease. Neurobiol Aging 1996 ; 17:753-9.
80. Sheng JG, Ito K, Skinner RD, Mrak RE, Rovnaghi CR, Van Eldik LJ, Griffin WS. In vivo and in vitro evidence supporting a role for the inflammatory cytokine interleukin-1 as a driving force in Alzheimer pathogenesis. Neurobiol Aging 1996 ; 17:761-6.
81. Prusiner S. Prions and neurodegenerative diseases. N Engl J Med 1987 ; 317:1571-81.
82. Friedland R, May C, Dahlberg G. The viral hypothesis of the Alzheimer's disease. Arch Neurol 1990 ; 47:177-8.
83. Lin WR, Shang D, Itzhaki RF. Neurotropic viruses and Alzheimer disease. Interaction of herpes simplex type 1 virus and apolipoprotein E in the aetiology of the disease. Mol Chem Neuropathol 1996 ; 28:135-41.
84. Singh VK. Neuroimmunity: pathogenic implications for Alzheimer's disease. Gerontology 1997 ; 43:79-94.
85. Yan SD, Zhu H, Fu J, Yan SF et al. Proc Natl Acad Sci 1997 ; 94:5296-5301.
86. Ceballos-Picot I, Merad-Boudia M, Nicole A, Thevenin M, Hellier G, Legrain S, Berr C. Peripheral antioxidant enzyme activities and selenium in elderly subjects and in dementia of Alzheimer's type. Place of the extracellular glutathione peroxidase. Free Radic Biol Med 1996 ; 20:579-87.
87. Deibel MA, Ehman WD, Markesbery WR. Copper, iron, and zinc imbalances in severely degenerated brain regions in Alzheimer's disease : possible relation to oxidative stress. J Neurol Sci 1996 ; 143:137-42.
88. Smith MA, Richey Harris PL, Sayre LM, Beckman JS, Perry G. Widespreasd peroxynitrite-mediated damage in Alzheimer's disease. J Neurosci 1997 ; 17:2653-7.
89. Sinet PM, Ceballos-Picot I. Role of the free radicals in Alzheimer's disease and Down's syndrome. In Free radical in the brain ; Packer L, Prilikpo L, Hhristen Y. Springer Verlag 1992:91-8.
90. Kaltschmidt B, Uherek M, Volk B, Baeuerle PA. Transcription factor NF-kappaB is activated in primary neurons and in neurons surrounding early plaques from patients with Alzheimer's disease. Proc Natl Acad Sci 1997 ; 94:2642-7.
91. Iversen LL, Mortishire-Smith RJ, Pollack SJ et al. The toxicity in vitro of beta amyloid protein. Biochem J 1995 ; 311:1-16.
92. Kagan VE, Balakova RA, Koynova GM et al. Antioxidant protection of the brain against oxidative stress. In Free radical in the brain ; Packer L, Prilikpo L, Hhristen Y. Springer Verlag 1992:49-61.
93. Papolla MA, Sos M, Omar RA et al. Melatonin prevents death of neuroblastoma cells exposed to Alzheimer amyloid peptide. J Neurosci 1997 ; 17:1683-90.
94. Mortimer JA, Van Duijn CM, Chandra V et al. Head trauma analysis as a risk factor for Alzheimer's disease: a collaborative reanalysis of case-control studies. Int J Epidemiol 1991 ; 20(suppl. 2):S28-35.
95. Smalheiser NR, Swanson DR. Linking estrogen to Alzheimer's disease: an informatics approach. Neurology 1996 ; 47:809-10.
96. Thal LJ. Potential prevention strategies for Alzheimer disease. Alzheimer Dis Assoc Disord 1996 ;10(suppl. 1):6-8.
97. Fratiglioni L. Epidemiology of Alzheimer's disease and current possibilities for prevention. Acta Neurol Scand (Suppl.) 1996 ; 165:33-40.
98. Kornhuber J, Weller M. Psychotogenicity and N-methyl-D-Aspartate receptor antagonism: implications for neuroprotective pharmacotherapy. Biol Psychiatry 1997 ; 41:135-44.
99. Koliatsos VE. Biological therapies for Alzheimer's disease: focus on trophic factors. Crit Rev Neurobiol 1996 ; 10:205-38.
100. Gozes I, Brenneman DE. Activity-dependent neurotrophic factor (ADNF). An extracellular neuroprotective chaperonin? J Mol Neurosci 1996 ; 7:235-44.